Related references
Note: Only part of the references are listed.Yttrium-labelled peptides for therapy of NET
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Anna Imhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry
Sebastien Baechler et al.
MEDICAL PHYSICS (2008)
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
L Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate
JJM Teunissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
